[From cancer to diabetes treatment : the tumor suppressor LKB1 as a new pharmacological target].
Foretz
Marc
M
Guigas
Bruno
B
Viollet
Benoît
B
D000091162:AMP-Activated Protein Kinase Kinases; D055372:AMP-Activated Protein Kinases; D000818:Animals; D017362:Cyclic AMP Response Element-Binding Protein / Q000502:physiology; D017868:Cyclic AMP-Dependent Protein Kinases / Q000502:physiology; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism / Q000517:prevention & control; D004789:Enzyme Activation / Q000187:drug effects; D005215:Fasting / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects*; D016147:Genes, Tumor Suppressor / Q000187:drug effects; D005943:Gluconeogenesis / Q000187:drug effects / Q000502:physiology*; D022781:Hepatocytes / Q000187:drug effects / Q000378:metabolism; D006706:Homeostasis; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007333:Insulin Resistance; D008099:Liver / Q000187:drug effects*; D020935:MAP Kinase Signaling System / Q000187:drug effects; D008687:Metformin / Q000494:pharmacology*; D051379:Mice; D018345:Mice, Knockout; D008954:Models, Biological; D009097:Multienzyme Complexes / Q000502:physiology; D009369:Neoplasms / Q000517:prevention & control*; D010580:Peutz-Jeghers Syndrome / Q000235:genetics; D010750:Phosphoproteins / Q000502:physiology; D017346:Protein Serine-Threonine Kinases / Q000172:deficiency / Q000235:genetics / Q000502:physiology*; D014157:Transcription Factors
C115163:CREB1 protein, human; C493245:CRTC2 protein, human; D017362:Cyclic AMP Response Element-Binding Protein; D007004:Hypoglycemic Agents; D009097:Multienzyme Complexes; D010750:Phosphoproteins; D014157:Transcription Factors; D008687:Metformin; D017346:Protein Serine-Threonine Kinases; C109790:STK11 protein, human; D017868:Cyclic AMP-Dependent Protein Kinases; D000091162:AMP-Activated Protein Kinase Kinases; D055372:AMP-Activated Protein Kinases